Aspire Biopharma Holdings Inc banner

Aspire Biopharma Holdings Inc
NASDAQ:ASBP

Watchlist Manager
Aspire Biopharma Holdings Inc Logo
Aspire Biopharma Holdings Inc
NASDAQ:ASBP
Watchlist
Price: 1.19 USD 13.33% Market Closed
Market Cap: $6m

Aspire Biopharma Holdings Inc
Investor Relations

Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engaged in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Kraig T. Higginson
President, CEO & Chairman of Board
No Bio Available
Mr. Ernest J. Scheidemann Jr.
Chief Financial Officer
No Bio Available
Mr. Stephen E. Quesenberry
General Counsel, Corporate Secretary & Director
No Bio Available

Contacts

Address
NEW YORK
Humacao
194 Candelaro Drive, #233
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett